Please login to the form below

Not currently logged in

FDA pauses BioMarin gene therapy trial

The study for BMN 307 in genetic disease phenylketonuria will be paused while malignancies in mice are explored

BioMarin logo The US Food and Drug Administration (FDA) has placed a clinical hold on the phase 1/2 Phearless study investigating BMN 307, a gene therapy from California-based rare disease biotech, BioMarin Pharmaceutical.

The Phearless study was investigating the AAV5-phenylalanine hydroxylase (PAH) gene therapy in adults with phenylketonuria (PKU), a genetic disorder affecting approximately 70,000 diagnosed patients in the regions of the world where BioMarin operates.

The hold was based on interim safety findings from a pre-clinical study that tested BMN 307 in mice with mutations that made them predisposed to develop malignancy. Six of the seven animals administered BMN 307 at the highest dose group developed liver tumours, five had adenomas and one a hepatocellular carcinoma.

The translatability of these findings to humans is uncertain and under further investigation, said BioMarin in a statement.

The Phearless study has already seen patients dosed with BMN 307, although the company stresses that this is at lower doses than in the mice studies, and that, due to previously identified risks, the liver health of participants is being monitored regularly.

“More than 3,000 patients have been treated with gene therapy, and there are no reports of cancers emerging as a consequence,” said BioMarin head of R&D, Hank Fuchs. However, he said that in acknowledgment of “the complexity of the issue”  the company would investigate further. “For patients who have already received lower doses of these vectors, we will continue to carefully evaluate and monitor their health. We are committed to understand and mitigate any risk of cancer causation.”

PKU is caused by a deficiency of the enzyme PAH, which is needed required for the metabolism of essential amino acid phenylalanine. Without active enzyme, the amino acid accumulates and becomes toxic to the brain, resulting in complications including severe intellectual disability, seizures, tremors, behavioural problems and psychiatric symptoms.

The core of BioMarin’s business is a portfolio of drugs for the treatment of mucopolysaccharidosis (MPS), which saw a rise in revenues of 17% in the second quarter of 2021. It’s products include Vimizim (elosulfase alfa) for MPS type IVA (Morquio A syndrome), Naglazyme (galsulfase) for MPS VI (Maroteaux-Lamy syndrome) and Kuvan (sapropterin dihydrochloride) in children with PKU.

Article by
Hugh Gosling

7th September 2021

From: Research, Regulatory, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
The digital-first launch: the key to connected stakeholder experiences?
During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...